

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

EXTENSION OF WAIVER REGARDING THE QUALIFICATION AND EXPERIENCE OF A JOINT COMPANY SECRETARY

Reference is made to the announcement of Alphamab Oncology (the “**Company**”) dated December 23, 2020 in which it is stated that The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) had granted a waiver to the Company from strict compliance with the requirements of Rule 3.28 and Rule 8.17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) regarding Ms. WANG Jin’nan (王晉南)’s (“**Ms. Wang**”) appointment as a joint company secretary of the Company (the “**Joint Company Secretary**”) for an initial period of three years from December 7, 2020 (being the date of Ms. Wang’s appointment as a Joint Company Secretary) (the “**Initial Waiver**”). The Initial Waiver was granted by the Stock Exchange on the condition that the Company appoints Ms. Chan Lok Yee (“**Ms. Chan**”), who meets the requirements under Note 1 to Rule 3.28 of the Listing Rules, to act as the other Joint Company Secretary to assist Ms. Wang in discharging her duties as a Joint Company Secretary and in gaining the relevant experience as required under Note 2 to Rule 3.28 of the Listing Rules.

To allow Ms. Wang to accumulate more experience and further enhance her training as a Joint Company Secretary, the Company has made a submission to the Stock Exchange to request that the Initial Waiver be extended (the “**Extended Waiver**”) for a period from December 7, 2023 to December 7, 2024 (the “**Extended Waiver Period**”).

The Stock Exchange has agreed to grant the Extended Waiver to Ms. Wang on December 18, 2023. The Extended Waiver is granted on the conditions that, among others, (i) Ms. Wang will be assisted by Ms. Chan during the Extended Waiver Period; and (ii) the waiver could be revoked if there are material breaches of the Listing Rules by the Company. In addition, Ms. Wang also undertakes to attend sufficient professional trainings during the Extended Waiver Period to fulfill the requirements under the Rule 3.29 of the Listing Rules. Before the end of the Extended Waiver Period, the Company will demonstrate and seek the Stock Exchange’s confirmation that Ms. Wang, having had the benefit of Ms. Chan’s assistance during the Extended Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under the Rule 3.28 of the Listing Rules so that a further waiver will not be necessary.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, December 19, 2023

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman and executive Director and Ms. LIU Yang as executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors.